No Data
No Data
No Data
Osecon (002755.SZ): net loss of 149 million yuan in 2023
On April 28, Ge Longhui (002755.SZ) released its 2023 annual report. During the reporting period, the company's operating income was 1,443 million yuan, a year-on-year decrease of 22.92%; net loss attributable to shareholders of listed companies was 149 million yuan; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was 227 million yuan; basic loss per share was 0.16 yuan/share.
Osecon (002755.SZ) announced first-quarter results, net profit of 31.5547 million yuan, turning a loss into a profit
According to Zhitong Finance App News, Osecon (002755.SZ) released its report for the first quarter of 2024. The company's operating income was 448 million yuan, up 32.47% year on year; net profit attributable to shareholders of listed companies was 31,5447 million yuan, which turned a loss into a profit; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 235.361 million yuan; basic income per share was 0.03 yuan/share.
Osecon (002755.SZ): The novel CMET inhibitor ASKC202 showed deep tumor remission and sustained anti-tumor signals
Osecon (002755.SZ) issued an announcement. Jiangsu Aosaikang Pharmaceutical Co., Ltd., a subsidiary of the company (hereinafter referred to as...
Osecon (002755.SZ): The subsidiary will present clinical research data for the innovative drug ASKC202 at the 2024 AACR Annual Meeting
Gelonghui, April 8, 丨 Osecon (002755.SZ) announced that Jiangsu Aosaikang Pharmaceutical Co., Ltd. (“Subsidiary”), a wholly-owned subsidiary of the company, first announced phase I (ASKC202-001) dose-increasing clinical trial data in the form of a poster at the American Association for Cancer Research (AACR) annual meeting on April 8, 2024.
Osecon (002755.SZ): Notice of acceptance of the subsidiary's application for drug registration and marketing approval for injectable delafloxacin
Gelonghui (002755.SZ) announced on March 4 that Jiangsu Osecon Pharmaceutical Co., Ltd. (“Subsidiary”), a wholly-owned subsidiary of the company, recently received the “Notice of Acceptance” of the marketing license application for injectable delafloxacin issued by the State Drug Administration. Delafloxacin (delafloxacin) is a next-generation broad-spectrum fluoroquinolone antimicrobial used in acute bacterial skin and structural skin infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
Osecon (002755.SZ) issued an advance loss. It is expected to lose a huge loss of 140 million yuan to 200 million yuan in 2023, and the loss will narrow
Osecon (002755.SZ) released the 2023 annual performance forecast, and the company expects 2023 to fall under the above...
No Data